Comorbidity Prevalence and Impact on Quality of Life in Gay and Bisexual Men Following Prostate Cancer Treatment

Overview

Journal Sex Med

Publisher Oxford University Press

Date 2021 Oct 11

PMID 34634579

Citations 7

Authors

Ryan Haggart

Elizabeth Polter

Michael Ross

Nidhi Kohli

Badrinath R Konety

Darryl Mitteldorf

William West

B R Simon Rosser

Affiliations

Soon will be listed here.

Abstract

Introduction: Studies have demonstrated worse health related quality of life (HRQOL) outcomes in gay and bisexual men (GBM) following prostate cancer treatment compared to heterosexual men potentially due to differences in comorbidity burden.

Aim: To establish the prevalence of comorbidities and their association with HRQOL metrics in GBM following prostate cancer treatment.

Methods: We evaluated HRQOL and prevalence of comorbidities in 193 GBM from the United States and Canada in a cross-sectional, online survey: the Masked for Review. HRQOL was measured with the Expanded Prostate Cancer Index Composite (EPIC) and the 12-Item Short Form Health Survey (SF-12).

Main Outcome Measures: Our outcomes included comorbidity prevalence, mean differences for HRQOL scores by comorbidity status, and mean differences for HRQOL by comorbidity count.

Results: GBM were found to have a higher prevalence of blood vessel disease and mental health disorders but lower prevalence of obesity and type 2 diabetes when compared to published data in general prostate cancer populations. Statistically significant reductions in HRQOL metrics were associated with mental health diagnoses, diabetes, and obesity. Increased number of comorbidities was also associated with reductions in HRQOL metrics in nearly all categories.

Conclusion: These results suggest that the worse QOL outcomes in GBM following prostate cancer treatment may be due to differences in comorbidity burden. This study is the first to evaluate the relationship between comorbidities and HRQOL outcomes in GBM. Limitations of this study include a small sample size and cross-sectional study design. If confirmed in larger, longitudinal, clinically confirmed studies, these findings indicate a need to intervene on and consider comorbidities in GBM diagnosed with prostate cancer. Haggart R, Polter E, Ross M, et al. Comorbidity Prevalence and Impact on Quality of Life in Gay and Bisexual Men Following Prostate Cancer Treatment. Sex Med 2021;9:100439.

Citing Articles

Does sexual rehabilitation work for gay and bisexual prostate cancer patients? Acceptability, feasibility, and efficacy results from the Restore-2 randomized controlled trial.

Rosser B, Kohli N, Bates A, Talley K, Wright M, Polter E J Cancer Surviv. 2024; .

PMID: 39266938 DOI: 10.1007/s11764-024-01672-6.

"Ultimately, You Realize You're on Your Own": The Impact of Prostate Cancer on Gay and Bisexual Men Couples.

Daniels J, Stephenson R, Langer S, Northouse L, Odouli R, Amarasekera C Int J Environ Res Public Health. 2023; 20(10).

PMID: 37239485 PMC: 10218571. DOI: 10.3390/ijerph20105756.

Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life.

Yazdanpanah O, Benjamin D, Kalebasty A Cancers (Basel). 2023; 15(9).

PMID: 37174119 PMC: 10177609. DOI: 10.3390/cancers15092654.

A Learning Health System Approach to Cancer Survivorship Care Among LGBTQ+ Communities.

Dunne W, Adebayo N, Danner S, Post S, OBrian C, Tom L JCO Oncol Pract. 2022; 19(1):e103-e114.

PMID: 36475752 PMC: 10166358. DOI: 10.1200/OP.22.00386.

LGBTQI cancer patients' quality of life and distress: A comparison by gender, sexuality, age, cancer type and geographical remoteness.

Ussher J, Allison K, Perz J, Power R Front Oncol. 2022; 12:873642.

PMID: 36203463 PMC: 9530284. DOI: 10.3389/fonc.2022.873642.

References

Thomas R, Burger R, Harper A, Kanema S, Mwenge L, Vanqa N . Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. Lancet Glob Health. 2017; 5(11):e1133-e1141. PMC: 5640509. DOI: 10.1016/S2214-109X(17)30367-4. View

Ware Jr J, Kosinski M, Keller S . A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-33. DOI: 10.1097/00005650-199603000-00003. View

Clement N, MacDonald D, Simpson A . The minimal clinically important difference in the Oxford knee score and Short Form 12 score after total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2013; 22(8):1933-9. DOI: 10.1007/s00167-013-2776-5. View

Skolarus T, Dunn R, Sanda M, Chang P, Greenfield T, Litwin M . Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2014; 85(1):101-5. PMC: 4274392. DOI: 10.1016/j.urology.2014.08.044. View

Wassersug R, Lyons A, Duncan D, Dowsett G, Pitts M . Diagnostic and outcome differences between heterosexual and nonheterosexual men treated for prostate cancer. Urology. 2013; 82(3):565-71. DOI: 10.1016/j.urology.2013.04.022. View

Droz J, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S . Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol. 2017; 72(4):521-531. DOI: 10.1016/j.eururo.2016.12.025. View

Punnen S, Cowan J, Dunn L, Shumay D, Carroll P, Cooperberg M . A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013; 112(2):E67-75. DOI: 10.1111/bju.12209. View

Guzzo T, Dluzniewski P, Orosco R, Platz E, Partin A, Han M . Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology. 2010; 76(3):553-7. PMC: 3643003. DOI: 10.1016/j.urology.2010.02.069. View

Tyson M, Andrews P, Etzioni D, Ferrigni R, Humphreys M, Swanson S . Marital status and prostate cancer outcomes. Can J Urol. 2013; 20(2):6702-6. View

10.

Dowsett G, Lyons A, Duncan D, Wassersug R . Flexibility in Men's Sexual Practices in Response to Iatrogenic Erectile Dysfunction after Prostate Cancer Treatment. Sex Med. 2014; 2(3):115-20. PMC: 4184491. DOI: 10.1002/sm2.32. View

11.

Cochran S, Mays V . Physical health complaints among lesbians, gay men, and bisexual and homosexually experienced heterosexual individuals: results from the California Quality of Life Survey. Am J Public Health. 2007; 97(11):2048-55. PMC: 2040376. DOI: 10.2105/AJPH.2006.087254. View

12.

Newlin Lew K, Dorsen C, Long T . Prevalence of Obesity, Prediabetes, and Diabetes in Sexual Minority Men: Results From the 2014 Behavioral Risk Factor Surveillance System. Diabetes Educ. 2018; 44(1):83-93. DOI: 10.1177/0145721717749943. View

13.

Salinas C, Tsodikov A, Ishak-Howard M, Cooney K . Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014; 11(6):317-23. PMC: 4191828. DOI: 10.1038/nrurol.2014.91. View

14.

Ussher J, Perz J, Kellett A, Chambers S, Latini D, Davis I . Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men. J Sex Med. 2016; 13(3):425-34. DOI: 10.1016/j.jsxm.2015.12.026. View

15.

Chambers S, Ng S, Baade P, Aitken J, Hyde M, Wittert G . Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer. Psychooncology. 2016; 26(10):1576-1585. PMC: 5655930. DOI: 10.1002/pon.4342. View

16.

Motofei I, Rowland D, Popa F, Kreienkamp D, Paunica S . Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal. BJU Int. 2010; 108(1):110-5. DOI: 10.1111/j.1464-410X.2010.09764.x. View

17.

Hart T, Coon D, Kowalkowski M, Zhang K, Hersom J, Goltz H . Changes in sexual roles and quality of life for gay men after prostate cancer: challenges for sexual health providers. J Sex Med. 2014; 11(9):2308-17. PMC: 4415517. DOI: 10.1111/jsm.12598. View

18.

Everett B, Mollborn S . Differences in hypertension by sexual orientation among U.S. young adults. J Community Health. 2013; 38(3):588-96. PMC: 3642207. DOI: 10.1007/s10900-013-9655-3. View

19.

Hah Y, Lee K, Choi I, Lee J, Hong J, Kim C . Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy: A retrospective competing-risk analysis from the K-CaP registry. Medicine (Baltimore). 2018; 97(42):e12766. PMC: 6211932. DOI: 10.1097/MD.0000000000012766. View

20.

Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B . Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2012; 63(4):693-701. DOI: 10.1016/j.eururo.2012.08.054. View